Phase 3 Study of Solifenacin Succinate and Mirabegron SYNERGY

• Research type

  Research Study

• Full title

  A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multi-center Study to Evaluate the Efficacy, Safety and Tolerability of Combinations of Solifenacin Succinate and Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in the Treatment of Overactive Bladder

• IRAS ID

  136509

• Contact name

  Timothy Robinson

• Contact email

  dudley.robinson@nhs.net

• Sponsor organisation

  Astellas Pharma Europe B.V.

• Eudract number

  2012-005735-91

• ISRCTN Number

  ISRCTN

• Clinicaltrials.gov Identifier

  NCT

• REC name

  London - Central Research Ethics Committee

• REC reference

  13/LO/1336

• Date of REC Opinion

  12 Nov 2013

• REC opinion

  Further Information Favourable Opinion